Legal Risks For Providers Discussing Psychedelic Therapies
With the U.S. Food and Drug Administration's rejection of the new drug application for methylenedioxymethamphetamine-assisted psychotherapy to treat post-traumatic stress disorder in August 2024, hopes for psychedelic therapies immediately entering mainstream clinical practice...To view the full article, register now.
Already a subscriber? Click here to view full article